Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3026% above fair value
$538.60−4.02 (-0.74%)
Close on Nov 13, 2026Market cap $136.51BP/E 31.4Yield –
Vertex Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Vertex Pharmaceuticals's pe ratio was 31.8× on Nov 11, 2026, against 30.5× a year earlier. Over the last 5 years it ranged from 19.2× to 33.0×, with a median of 27.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 31.8× | −0.0 |
| 2025 | Dec 31, 2025 | 31.9× | −0.3 |
| 2024 | Jul 31, 2024 | 32.2× | +1.6 |
| 2023 | Dec 29, 2023 | 30.5× | +7.8 |
| 2022 | Dec 30, 2022 | 22.8× | −3.6 |
| 2021 | Dec 31, 2021 | 26.4× | +3.3 |
| 2020 | Dec 31, 2020 | 23.1× | −3.4 |
| 2019 | Dec 31, 2019 | 26.5× | −39.7 |
| 2018 | Dec 31, 2018 | 66.3× | −125.8 |
| 2017 | Dec 29, 2017 | 192.1× | +116.2 |
| 2013 | Jan 31, 2013 | 75.9× | +4.9 |
| 2012 | Dec 31, 2012 | 71.0× | – |
See a number that looks wrong?